(Bloomberg) — Bayer AG’s plan for moving on from its Roundup legal woes hit a snag barely two weeks after it announced a settlement of claims against the weedkiller when a judge expressed skepticism over part of the proposal.U.S. District Judge Vince Chhabria wrote in a court filing Monday that a proposed system for dealing with future lawsuits over the herbicide is problematic. Shares of Bayer, which inherited the weedkiller through its purchase of Monsanto, fell as much as 6.9% in Frankfurt, the most intraday since March 23.The judge’s misgivings center on a plan to create a class of future claims as part of the nearly $11 billion settlement. Any change to that portion of the proposal wouldn’t necessarily affect the rest of the deal, in which the company agreed to resolve about 125,000 existing lawsuits.About 30,000 claims, contending that Roundup caused non-Hodgkin’s lymphoma, are not yet subject to deals between plaintiffs and Bayer. Some U.S. plaintiffs’ lawyers are vowing to file another wave of new suits that could add tens of thousands to that total.Chhabria set a July 24 hearing to consider the class-action proposal, which he said he’s “tentatively inclined” to reject. That portion of the plan would establish a scientific panel to determine whether Roundup’s active ingredient causes cancer, while still potentially allowing users of the herbicide to press claims.Concerned InvestorsThe judge’s filing reinforces concerns from investors that Bayer’s Roundup deal isn’t enough to get it beyond the mountain of litigation, Alistair Campbell, an analyst at Liberum Capital, said in a note. While Bayer’s market valuation is “deeply discounted” right now, that situation probably won’t change until the company can convince the market that it’s finally resolved the Roundup legal headache.Bayer said late Monday the class proposal is still on the table. The company — whose shares are down about 9% since it announced the settlement on June 24 — insists that Roundup is safe and has appealed three U.S. verdicts against it.“We appreciate the judge’s order raising his preliminary concerns with the proposed class settlement, which we take seriously and will address” at the hearing, Chris Loder, a U.S.-based spokesman for the Leverkusen, Germany-based drugmaker, said in an interview.Future Cases“Thankfully, Judge Chhabria has seen the ruthless plan as an outrageous attempt to deprive every future victim of Monsanto’s killer Roundup of their right to fair and full compensation and to a jury trial,” Tom Kline and Jason Itkin, plaintiffs attorneys for users of the weedkiller who haven’t settled their suits, said in an emailed statement Tuesday.The futures class was the brainchild of Bayers’ lawyers and some plaintiffs’ attorneys , including San Francisco-based Elizabeth Cabraser and Samuel Issacharoff, a New York University law professor, according to court filings. It took a year of “unrelenting” settlement negotiations to come up with the plan, Cabraser said in a court filing. It’s designed to provide funds to Roundup cancer patients in financial need and finance a review of the science underlying the cancer claims.William Dodero, Bayer’s global head of litigation, said at a press conference last month he couldn’t predict how many new Roundup cases will emerge and need to be included in the futures class. He said the class will feature an independent science panel that will decide whether glyphosate –- Roundup’s active ingredient — is a carcinogen rather than leave the decision to individual judges and juries.Read More: Bayer Isn’t Out of the Roundup Woods as 30,000 Claims RemainThree California juries orderered Bayer to pay billions of dollars in combined damages based on findings that glyphosate caused the plaintiffs’ cancers. Those awards ultimately were reduced to about $190 million.The science panel is designed to have independent experts make the decision on the chemical’s toxicity, Dodero said.“They will be selected by the parties by mutual agreement, and if there is not mutual agreement each party will select two; the four will select the remaining fifth,” he said last month. “They will be objective and a blue-ribbon panel to fully assess the evidence.”If the panel finds glyphosate is not a carcinogen, then class members would be barred from recovering from their cases, according to court filings. Conversely, if the panel says the chemical can cause cancer, future Roundup users could proceed with their suits.Sticking PointThat’s one of the sticking points with the class-action mechanism, Chhabria said.“It’s questionable whether it would be constitutional (or otherwise lawful) to delegate the function of deciding the general causation question (that is, whether and at what dose Roundup is capable of causing cancer) from judges and juries to a panel of scientists,” he said.He also questioned whether there is an incentive to join the class for future Roundup claimants, who would have five months after the class is approved to opt out of it.“Why would a potential class member want to replace a jury trial and the right to seek punitive damages with the process contemplated by the settlement agreement?” the judge asked.He also said the proposal has procedural drawbacks in making sure all potential future Roundup claimants have proper notice that they must decide within five months whether to become part of the class.NFL Comparison“Given the diffuse, contingent, and indeterminate nature of the proposed class, it seems unlikely that most class members would have an opportunity to consider in a meaningful way (if at all) whether it is in their best interest to join the class,” he said.The Roundup litigation isn’t the first to generate a settlement that addresses future claims.But unlike the National Football League’s 2014 concussion settlement — slated to provide at least $765 million to ex-players suffering from brain injuries now and in the future –- the Roundup futures class doesn’t apply to a “narrow and readily identifiable” set of claimants, Chhabria said. The NFL’s futures class won approval from an appeals court in 2016.“A class that includes all Roundup users who will get cancer in the future is very different,” the judge said. “For example, the idea that a migrant farmworker or someone who is employed part time by a small gardening business would receive proper notification (much less the opportunity to consider their options in a meaningful way) is dubious.”The consolidated case is In re: Roundup Products Liability Litigation, MDL 2741, U.S. District Court, Northern District of California (San Francisco).(Updates with analyst commentary in sixth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
from Yahoo Finance https://ift.tt/3e7i45x
American Airlines is telling the U.S. Department of Transportation your pet dog cannot apply for a credit card. Nor can you apply for a credit card using other fraudulent means. Lawyers for the airline made that clear this week in a 53-page document alleging some loyalty program members recently took part in an "elaborate scheme […]
Nio Shares charged over 20% higher Monday on better-than-expected June sales.
A look at the shareholders of Overstock.com, Inc. (NASDAQ:OSTK) can tell us which group is most powerful. Institutions…
Shares in Novavax (NVAX) are currently jumping 42% in pre-market trading after the biotech company said that it has been granted $1.6 billion by the U.S. government to fund the development of a potential coronavirus vaccine.The stock is soaring to $116.53 in Tuesday’s pre-market trading as Novavax announced that it has been selected to participate in Operation Warp Speed (OWS), a U.S. government program that seeks to begin supplying millions of doses of a safe, effective vaccine for COVID-19 in 2021. As part of the program, Novavax has been awarded with the funding to complete its late-stage clinical development, including a pivotal Phase 3 clinical trial of its COVID-19 candidate NVX‑CoV2373 and supply 100 million doses of the vaccine as early as late 2020.“The pandemic has caused an unprecedented public health crisis. We are honored to partner with Operation Warp Speed to move our vaccine candidate forward with extraordinary urgency in the quest to provide vital protection to our nation’s population,” said Novavax CEO Stanley C. Erck. “We are grateful to the U.S. government for its confidence in our technology platform, and are working tirelessly to develop and produce a vaccine for this global health crisis.”NVX‑CoV2373 consists of a stable, prefusion protein made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M adjuvant. In May, Novavax initiated a Phase 1/2 clinical trial of NVX-CoV2373 in 130 healthy participants 18 to 59 years of age began in Australia. Preliminary immunogenicity and safety results from the trial are expected at the end of July, and the Phase 2 portion to assess immunity, safety, and COVID-19 disease reduction is expected to begin thereafter. The Phase 1/2 clinical trial is being supported by an up-to $388 million funding arrangement with the Coalition for Epidemic Preparedness Innovations (CEPI).In the run-up to developing a coronavirus vaccine, the stock has this year gone up almost 20 times in value. However, shares dropped 5% this month, prompting B. Riley FBR analyst Mayank Mamtani to recommend investors take advantage of the stock weakness.At the same time, Mamtani reiterated his Buy rating on the stock with a $106 price target, suggesting that despite this year’s rally shares are poised to gain another 33% over the coming 12 months.The rest of the Street shares Mamtani’s outlook. The Strong Buy analyst consensus is backed up by 4 Buy ratings versus 1 Hold rating. Meanwhile, the $75.80 average price target indicates 4.6% downside potential from current levels. (See Novavax stock analysis on TipRanks).Related News: Cellectis Sinks 13% In Extended Trading After FDA Halts Cancer Clinical Trial Chembio Gains 12% After-Hours On New Covid-19 BARDA Contract Gilead’s Covid-19 Remdesivir Therapy Gets Conditional European Nod More recent articles from Smarter Analyst: * Microsoft Mulls Acquisition of Warner Bros.’ Gaming Unit – Report * Microsoft To Reveal New Games Lineup With Xbox Series X Event This Month * Otonomy Pops 15% in Pre-Market Fueled By Otividex Data, Positive Results From Tinnitus Candidate * Bellus Health Craters 72% On Chronic Cough Miss; Analyst Still Says Buy
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
The impact of COVID-19 is still being felt within markets. Sam Stovall, Chief Investment Strategist at CFRA joins The Final Round to break down what that might look like in Q2.The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]